2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Diseases, Immunology, Neutropenia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3929 Inhibition of IGF2BP2-driven pseudohypoxia overcomes proteasomal-bypass bortezomib resistance in multiple myeloma

Colton Henry Dysart, BS, Nathaniel J Buteyn, PhD2, Tim Triche Jr, PhD3
1 Van Andel Institute, Grand Rapids, Michigan, United States
2 Van Andel Institute, Grand Rapids, Michigan, United States
3 Michigan State University, East Lansing, Michigan, United States, University of Southern California, Los Angeles, California, United States, Van Andel Institute, Grand Rapids, Michigan, United States

Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable despite substantial improvements in outcomes achieved with proteasome inhibitor (PI)-based regimens (bortezomib, carfilzomib, ixazomib); however, acquired resistance almost universally emerges. Elevated mTOR activity, observed in patients with aberrant FGFR3 signaling, has been shown to correlate with resistance to bortezomib through a variety of mechanisms. Given the conservation of downstream signaling among FGFR family members, we hypothesized that FGFR1 overexpression could phenocopy this biology independent of translocation. Analysis of diagnostic RNA-seq from the MMRF CoMMpass cohort (n=858) confirmed that FGFR1-overexpressing MM recapitulates the MAPK/PI3K/mTOR signaling signature of PI-resistant disease within a translocation-diverse patient subset. FGFR1 expression correlated strongly with the mTOR substrate and m6A reader IGF2BP2 (Pearson r = 0.529, p-val = 5.03E-63), an oncofetal RNA-binding protein that stabilizes m6A-modified transcripts by shielding them from YTHDF2-mediated decay. Oncogenic transcripts stabilized by IGF2BP2 include MYC, KRAS, and HIF1A. We demonstrated that pharmacologic IGF2BP2 inhibition (CWI1-2) markedly reduced MYC protein levels in MM cell lines, confirming on-target activity.

Among IGF2BP2 targets, HIF1A is of particular mechanistic interest: IGF2BP2-mediated stabilization may sustain HIF-1α accumulation independent of oxygen tension, establishing a pseudohypoxic state that transcriptionally upregulates autophagy initiation machinery and enables autophagic clearance of misfolded protein as a bypass of proteasomal degradation. To interrogate the pseudohypoxic phenotype directly, we examined autophagy pathway gene signatures in IGF2BP2HIGH versus LOW MMRF patients and observed upregulation of HIF1A alongside initiation (ULK1, ATG13), nucleation (BECN1, ATG14, PIK3C3, ATG12, ATG5, ATG7), and maturation (MAP1LC3B, ATG3) of autophagy machinery, consistent with increased LC3-II lipidation and autophagosome biogenesis. Functionally, IGF2BP2HIGH (SK-MM-1) and IGF2BP2LOW (ANBL-6) MM lines were treated with CWI1-2 (500 nM) and/or bortezomib (50 nM). IGF2BP2HIGH cells were intrinsically resistant to bortezomib monotherapy (no significant viability loss versus a decline to 20% viability in IGF2BP2LOW cells at 24 hours). Following 96 hours of CWI1-2 conditioning, combination treatment showed a marked synergistic reduction in viability to 55%, compared with 92% and 72% with either single agent, indicating that IGF2BP2 inhibition resensitizes intrinsically resistant cells to PI-induced cytotoxicity.

These data suggest autophagy-mediated proteasomal bypass, downstream of an FGFR-mTOR-IGF2BP2-HIF1A signaling axis, as a previously unrecognized and pharmacologically actionable mechanism of PI resistance in MM. FGFR1, expressed on the cell surface, may serve as an accessible, translocation-independent biomarker for PI-resistant disease.

Colton Henry Dysart, BS: No relevant conflicts of interest to declare.